Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28002539 | 0.84 | L3MBTL1 (0.44) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL287761 | 0.83 | LMNA (0.47) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL27417392 | 0.81 | LMNA (0.42) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| Hydrochloric Acid SCHEMBL20139726 | 0.81 | LMNA (0.46) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL2760820 | 0.81 | PLAU (0.48) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL23413510 | 0.81 | LMNA (0.46) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL30143410 | 0.81 | PLAU (0.48) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL7692886 | 0.81 | LMNA (0.42) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL29669873 | 0.79 | GPR27 (0.42) | L3MBTL1LMNAPLAUGPR27CYP2C9 | |
| SCHEMBL17224852 | 0.79 | PLAU (0.44) | L3MBTL1PLAUMAPK1HCAR2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-116874441-A | Flexible aryl formamide derivative containing 1,2, 4-oxadiazole as well as preparation method and application thereof | 贵州大学 | 2023-10-13 | — | — | CN | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| CN-107683283-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10696691-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2016055496-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008031513-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
| US-5166352-A | Pyridinecarboxylic acid chlorides from (trichloromethyl)pyridines | DOWELANCO (US) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885LMNA 3196/4885PLAU 2381/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885LMNA 3153/4885PLAU 2332/4885 |
| US-10696691-B2 | BACE1 inhibitors | BACE1, BACE2, APP | L3MBTL1 3525/4885LMNA 1143/4885PLAU 1410/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885LMNA 3153/4885PLAU 2332/4885 |
| US-20160102105-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | L3MBTL1 3525/4885LMNA 1143/4885PLAU 1410/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885LMNA 3196/4885PLAU 2381/4885 |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | PDE3A, PDE2A, PDE3B | L3MBTL1 4569/4885LMNA 2042/4885PLAU 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.